Early Lapatinib-Induced Skin Rash Predicts Better Survival With Lapatinib+Trastuzumab Therapy - Cancer Therapy Advisor

Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.

Molecules, Free Full-Text

Neoadjuvant Therapy in HER2-Positive Breast Cancer: Ready for

Page 1540 – Cancer Therapy Advisor

A Phase 1B open-label study of gedatolisib (PF-05212384) in

Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast

Lapatinib and lapatinib plus trastuzumab therapy versus

Page 1526 – Cancer Therapy Advisor

Radiotherapy as a tool to elicit clinically actionable signalling

Frontiers Dermatologic Toxicities of Targeted Therapy and

Page 1526 – Cancer Therapy Advisor

Lapatinib and lapatinib plus trastuzumab therapy versus